Home › Companies › TARA

Protara Therapeutics

TARA Rare disease Lead: Phase 3 8 Biotech Distilled articles ↓

Dermatology Metabolic Oncology Cell Small Molecule

Most recent annual filing: 2026-03-10

Pipeline (3 active programs)

TARA-002

Cell Target: TLR2, NOD2

Non-Muscle Invasive Bladder Cancer Phase 2 intravesical
Pediatric Lymphatic Malformations Phase 2

IV Choline Chloride

choline chloride

Choline Deficiency Phase 3 intravenous

Biotech Distilled coverage (8)

2026-06-30 UPDATE: Protara Therapeutics (TARA) - The CMO Walks on Warrant Deadline Day
2026-05-16 UPDATE: Protara Therapeutics (TARA) - The BCG-Naïve 12-Month Holds 🔒 Paid
2026-05-15 UPDATE: Protara Therapeutics (TARA) - The ATM Goes Live 🔒 Paid
2026-05-14 UPDATE: Protara Therapeutics (TARA) - Q1 2026 Status Check 🔒 Paid
2026-04-27 UPDATE: Protara Therapeutics (TARA) - The Warrant Trigger Trips 🔒 Paid
2026-03-15 UPDATE: Protara Therapeutics (TARA) - FY25 Earnings 🔒 Paid
2026-03-01 UPDATE: Protara Therapeutics (TARA) - ASCO GU Update 🔒 Paid
2026-02-23 Protara Therapeutics (TARA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.